Literature DB >> 12120912

Serum beta 2-microglobulin reflects disease activity in Behçet's disease.

Mustafa Aygündüz1, Nüket Bavbek, Mustafa Oztürk, Osman Kaftan, Ali Koşar, Serafettin Kirazli.   

Abstract

Behçet's disease (BD) is a systemic remitting vasculitis characterized by orogenital ulceration and uveitis. The disease is not associated with specific laboratory abnormalities. Hence, the activity of BD is generally assessed by clinical findings and--to some extent--by nonspecific markers of inflammation. This study was performed to investigate the relative efficiency of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serumamyloid A protein (SAA), and beta 2-microglobulin (beta 2-m) levels as markers of disease activity in patients with BD. The study population consisted of 20 patients with active BD, 23 patients with inactive BD, and 27 healthy adults serving as the control group. Serum beta 2-m, SAA, ESR, and CRP levels of patients with BD were found to be significantly higher than those in the healthy control group. They were also higher in patients with active disease than in those in remission and controls. The levels of SAA. ESR, and CRP in inactive patients were also significantly higher than the controls. No statistically significant difference was noted between beta 2-m levels of patients with inactive BD and healthy controls. Serum beta 2-m levels can beregarded as a more discriminative marker of activation in BD. The high diagnostic value of SAA levels indicate that it can also be accepted as a marker of disease activity in BD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12120912     DOI: 10.1007/s00296-002-0180-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  6 in total

1.  Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease.

Authors:  Bülent Yılmaz; Seyfettin Köklü; Osman Yüksel; Serap Arslan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Use of prognostic nutritional index in the evaluation of disease activity in patients with Behçet's disease.

Authors:  Nuh Ataş; Hakan Babaoğlu; Ertuğrul Demirel; Bülent Çelik; Reyhan Bilici Salman; Hasan Satış; Hazan Karadeniz; Aslıhan Avanoğlu Güler; Seminur Haznedaroğlu; Berna Göker; Abdurrahman Tufan; Mehmet Akif Öztürk
Journal:  Eur J Rheumatol       Date:  2020-07-21

Review 3.  Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome.

Authors:  M T Keogan
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

4.  Serum amyloid-A in Behçet's disease.

Authors:  Antonio Vitale; Donato Rigante; Giuseppe Lopalco; Maria Giuseppina Brizi; Francesco Caso; Rossella Franceschini; Rosario Denaro; Mauro Galeazzi; Leonardo Punzi; Florenzo Iannone; Giovanni Lapadula; Antonella Simpatico; Edoardo Marrani; Luisa Costa; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-08       Impact factor: 2.980

Review 5.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

6.  Serum β2-Microglobulin is Associated with Mortality in Hospitalized Patients with Exacerbated Chronic Obstructive Pulmonary Disease.

Authors:  Wenping Mao; Jing Wang; Liming Zhang; Ying Wang; Wenjun Wang; Na Zeng; Jun Zhang; Qian Li; Fengwei Jiao; Jie Li; Na Cui; Song Mi; Yi Xue; Zhaomei Wang; Sun Ying; Kewu Huang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.